Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Boruzu
(United States) [Available] ,Velcade
(United States) [Available]Synonyms :
bortezomib 
Class :
Antineoplastics and Proteasome Inhibitors
Brand Name :
Boruzu
(United States) [Available] ,Velcade
(United States) [Available]Synonyms :
bortezomib 
Class :
Antineoplastics and Proteasome Inhibitors
Adult:
Dosage Forms & Strengths
Injection-lyophilized powder for reconstitution
3.5mg/vial
Pediatric:Â
Safety and efficacy not established
Geriatric:
Refer adult dosing
when both drugs are combined, there may be an increase in the hypotensive effect of amifostine
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bortezomib
aminosalicylic acid derivatives
it may increase the myelosuppressive effect of myelosuppressive agents
when both drugs are combined, there may be an increase in the hypotensive effect of blood pressure-lowering agents
when both drugs are combined, there may be an increase in the hypotensive effect of hypotension-associated agents
it may increase or decrease the therapeutic effect of antidiabetic agents
it may increase the hypotensive effect of antipsychotic agents 
blood pressure lowering agents
it may increase the hypotensive effect of hypotension-associated agents
it may increase the serum concentration of bortezomib 
it may increase the hypotensive effect of hypotension-associated agents
it may decrease the serum concentration of Estrogen Derivatives
bazedoxifene/conjugated estrogens
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
it increases the efficacy of antidiabetic agents
it increases the efficacy of antidiabetic agents
it increases the efficacy of antidiabetic agents
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with bortezomib
bortezomib: they may increase the therapeutic effect of antidiabetic drugs
bortezomib: they may increase the therapeutic effect of antidiabetic drugs
bortezomib: they may increase the therapeutic effect of antidiabetic drugs
It may enhance the levels when combined with tamsulosin by affecting CYP2D6 metabolism
Combining bortezomib with pranlukast may cause a reduction in the bortezomib’s metabolism
Combining tegafur with bortezomib can reduce tegafur’s metabolism
When dexrabeprazole and bortezomib is used together, this leads to reduction in the dexrabeprazole’s metabolism
The potential for bleeding risk or its seriousness may elevate when bortezomib is used together with troxerutin
When acetohexamide is used together with bortezomib, this lead to reduction in acetohexamide’s metabolism
When bortezomib is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When bortezomib is used together with somatotropin, this leads to a rise in bortezomib’s metabolism
When ponesimod is used together with bortezomib, this leads to enhanced risk or seriousness of bradycardia
When bortezomib is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When bortezomib is used together with allylestrenol, this leads to a reduction in the bortezomib metabolism
When bortezomib is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
When bortezomib is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When bortezomib is used together with oleandomycin, this leads to enhanced concentration serum of bortezomib
When bortezomib is used together with patupilone, this leads to enhanced concentration serum of bortezomib
When bortezomib is used together with ridaforolimus, this leads to enhanced concentration serum of bortezomib
bortezomib: it may decrease the metabolism of oxtriphylline
bortezomib: it may increase the metabolism of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
bortezomib: it may decrease the metabolism of piperazine
bortezomib: it may decrease the metabolism of bamifylline
bortezomib: it may increase the risk of bleeding with trapidil
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be a high metabolism of bortezomib 
the effect of bortezomib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of bortezomib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of bortezomib in serum
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect of antidiabetic agents
it increases the effect of antidiabetic agents
fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents
may increase the therapeutic effect of Anti-diabetic Agents
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration of estrogen derivatives
the serum levels of bortezomib may be increased
the serum levels of bortezomib may be increased
When bortezomib is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
Actions:
The 26 S proteasome has chymotrypsin like activity in mammalian cells. It can inhibit by bortezomib. It is an important protein complex. It breaks down ubiquitinated proteins, regulates the levels of protein in the cells, and maintain the homeostasis of cell. When 26S proteasome is inhibited, targeted proteolysis is changed. It affects different signaling cascades in the cell and lead to cell death. Bortezomib has cytotoxic effects on many in-vitro cancer cell types by laboratory test.
Spectrum:
Bortezomib is approved by FDA for different diseases. It is used as an initial treatment to treat multiple myeloma when it is used along with cyclophosphamide and dexamethasone. It is approved to treat multiple myeloma in patients who have earlier responded to bortezomib and returned in 6 months after the treatment. It is approved to treat mantle cell lymphoma in patients who have gone for 1 earlier 1st line treatment. It is used as a non-approved drug to treat antibody mediated rejection in cardiac transplantation, Systemic light chain amyloidosis, relapsed or refractory cutaneous T-cell lymphomas, peripheral T-cell lymphoma, follicular lymphoma, and Waldenstrom macroglobulinemia.
Frequency defined
>10%
Asthenia
Diarrhea
Anorexia
Anemia
Arthralgia
Headache
Nausea
Thrombocytopenia
Peripheral neuropathy
Pyrexia
Vomiting
Insomnia
Limb pain
Neutropenia
Paresthesia
Rash
Cough
Dehydration
URI
Rigors
Frequency Not Defined
Hypotension
Abdominal pain
Dyspepsia
Back pain
Bone pain
Myalgia
Muscle spasms
Pain
Pruritus
When bortezomib is administrated to patients who have 3rd grade non-hematological or 4th grade hematological toxicity, treatment must be stopped temporarily until the toxicity is gone. Treatment can restart with a low and modified dosage after the resolution. The toxicity effects cannot be reversed by an antidote.
Contraindications
Hypersensitivity
Pregnancy
Breastfeeding
Cautions
Renal impairment
Thrombotic Microangiopathy (TTP/HUS)
Hepatic Impairment
Tumor Lysis Syndrome
Posterior Reversible Encephalopathy Syndrome (PRES)
Thrombocytopenia and Neutropenia
Hypotension
Gastrointestinal Effects
Pregnancy Risk
Congestive Heart Failure
Respiratory Issues like Acute respiratory distress syndrome (ARDS)
Pulmonary diseases like interstitial pneumonia and pneumonitis
Peripheral Neuropathy
Drug interactions
Pregnancy
Breastfeeding
Pregnancy warnings:Â
Breastfeeding warnings:
Pregnancy Categories:Â Â Â
Category N: There is no data available for the drug under this category
Pharmacology:
Bortezomib can stop a particular chymotrypsin activity in a cellular structure known as 26 S proteasome. This can lead to an end to a cell cycle and starts apoptosis process. It is a form of programmed cell death.
Pharmacodynamics:
Bortezomib dosages of 1 mg/m² and 1.3 mg/m² 2 times a week inhibit the activity of 20S proteasome in the whole blood which happened after the 5 minutes if drug administration. Maximum inhibition levels are observed between 2 dosage which can range from 70 to 80% for 1 mg/m2 and 73 to 83% for 1.3 mg/m2.
Pharmacokinetics:
Absorption
The amount which is reached to the blood is about 509 ng/mL after the administration.
Distribution
About 83 % of the bortezomib is attached to proteins. The volume of distribution varies from 498 to 1884 L/m2.
Metabolism
The metabolism is takes place in the liver by enzymes like CYP3A4 with minimal involvement of CYP1A2, 2C9, 2C19, and 2D6. It inhibits the activity of CYP2C19 enzymes.
Elimination and Excretion
The half life of the bortezomib is about 9 to 15 hours for a single IV dosage, 40 to 193 hours for a multiple 1 mg/m² dosages, and 76 to 108 hours for multiple 1.3 mg/m² dosages.
Bortezomib is combined with saline solution before the administration. Add specific amount to get the concentration of 1 mg/mL for IV usage. Add a different amount to get a concentration of 2.5 mg/mL for SC usage.
If any skin reactions occurred after administration through SC, a less concentrated solution 1 mg/mL is used subcutaneously. It is necessary not to use it intrathecally as it can be fatal. There must be 72 hours of time between the dosages. The medication is given as a quick IV injection or subcutaneous injection in the thigh or abdomen.
It is necessary to take proper precautions to handle and dispose it. Protect it from the direct sunlight. Unused vial must be stored at a room temperature. Use the regenerated solution in 8 hours.
Generic Name: bosutinib Â
Pronounced: boh-SOO-tih-nibÂ
Why do we use bosutinib?Â
Bosutinib is used to manage Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). It is a tyrosine kinase inhibitor that blocks the activity of BCR-ABL and Src kinases—proteins that are typically overactive in CML and contribute to the uncontrolled growth of cancer cells.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
